Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Gladstone DE, Petri M, Bolaños-Meade J, Dezern AE, Jones RJ, Fine D, Brodsky RA.

Lupus. 2017 Jun;26(7):773-776. doi: 10.1177/0961203316669242. Epub 2016 Sep 30.

2.

High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus.

Lisukov IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, Zonova EV, Chernykh ER, Leplina OY, Sentyakova TN, Demin AA, Kozlov VA.

Lupus. 2004;13(2):89-94.

PMID:
14995000
3.

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.

Petri M, Jones RJ, Brodsky RA.

Arthritis Rheum. 2003 Jan;48(1):166-73.

4.

Autologous stem cell transplantation for systemic lupus erythematosus.

Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, Tyndall A; European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry.

Lupus. 2004;13(3):168-76.

PMID:
15119545
5.
6.

Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.

Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6. doi: 10.1016/j.bbmt.2013.01.006. Epub 2013 Jan 29.

7.

Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase.

Okamoto S, Watanabe R, Takahashi S, Mori T, Izeki T, Nagayama H, Ishida A, Takayama N, Yokoyama K, Tojo A, Asano S, Ikeda Y.

Int J Hematol. 2002 Jun;75(5):493-8.

PMID:
12095149
8.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ.

Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.

9.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

10.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

12.

A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation.

Leng XM, Zhao Y, Zhou DB, Situ H, Li TS, Shen T, Zhao YQ, Zeng XF, Zhang FC, Dong Y, Tang FL.

Chin Med Sci J. 2005 Sep;20(3):159-65.

PMID:
16261884
13.
14.

Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.

Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.

Bone Marrow Transplant. 1996 May;17(5):685-9.

PMID:
8733682
16.

Modern approaches to HLA-haploidentical blood or marrow transplantation.

Kanakry CG, Fuchs EJ, Luznik L.

Nat Rev Clin Oncol. 2016 Jan;13(1):10-24. doi: 10.1038/nrclinonc.2015.128. Epub 2015 Aug 25. Review. Erratum in: Nat Rev Clin Oncol. 2016 Feb;13(2):132.

17.

Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.

Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH.

Bone Marrow Transplant. 2007 Sep;40(5):423-30. Epub 2007 Jul 2.

PMID:
17603516
18.
19.

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.

Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH.

Blood. 1998 Nov 15;92(10):3505-14.

20.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ.

Biol Blood Marrow Transplant. 2003 May;9(5):312-9.

Supplemental Content

Support Center